secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001193125-25-174943
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom Q2 revenue $39.5M, up from $7.3M YoY; 580k+ VOQUEZNA scripts filled
---------------------------------------------------------------------------

- Net revenues $39.5M in Q2 2025 vs $7.3M in Q2 2024; net loss $75.8M vs $91.4M YoY.
- Over 580k total VOQUEZNA prescriptions filled (+49% since May 1); ~173k in Q2 (36% sequential growth).
- 10-year NCE exclusivity for VOQUEZNA 10mg/20mg tablets through May 2032; generic entry unlikely before 2033.
- Full-year 2025 revenue guidance $165M-$175M; expects non-GAAP OpEx <$60M in Q3 and <$55M in Q4.
- Appointed Anne Marie Cook as Chief Legal Officer and Corporate Secretary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312525174943/0001193125-25-174943-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312525174943/d907916d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-174943

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer